Loading…

Development of a depot formulation with an in situ non-lamellar liquid crystal-forming system with phospholipids

Non-lamellar liquid crystal (NLLC) structures have gained increasing attention for the controlled release of entrapped drugs. In the present study, an in situ NLLC structure-forming depot formulation through contact with water was developed using a ternary mixture system of soya phosphatidyl choline...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in Drug Delivery 2023-10, Vol.3
Main Authors: Todo, Hiroaki, Niki, Rina, Okada, Akie, Narita, Ibuki, Inamura, Kazuya, Ito, Ayu, Itakura, Shoko, Hijikuro, Ichiro, Sugibayashi, Kenji
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2464-b527753ee4cfe7485b383930e4f1618f84b6696f70199c5b0a11e227d3ad1f7d3
cites cdi_FETCH-LOGICAL-c2464-b527753ee4cfe7485b383930e4f1618f84b6696f70199c5b0a11e227d3ad1f7d3
container_end_page
container_issue
container_start_page
container_title Frontiers in Drug Delivery
container_volume 3
creator Todo, Hiroaki
Niki, Rina
Okada, Akie
Narita, Ibuki
Inamura, Kazuya
Ito, Ayu
Itakura, Shoko
Hijikuro, Ichiro
Sugibayashi, Kenji
description Non-lamellar liquid crystal (NLLC) structures have gained increasing attention for the controlled release of entrapped drugs. In the present study, an in situ NLLC structure-forming depot formulation through contact with water was developed using a ternary mixture system of soya phosphatidyl choline (SPC), 1, 2-dioleoyl- sn -glycero-3-phosphoglycerol sodium salt (DOPG), and sorbitan trioleate (Span 85), and the long-term release of an entrapped model drug, leuprolide acetate (LA), was investigated using evaluation of in vitro release and in vivo blood concentration–time profiles. Polarized images and small angle X-ray scattering analysis were used to confirm the presence of NLLC structures by contacting the prepared formulation with water. In addition, LA release and blood concentration–time profiles were investigated using in vitro and in vivo experiments, respectively. In situ NLLC constructed formulations by contacting water were achieved using a ternary mixture of SPC, DOPG, and Span 85. In particular, negative curvature was increased with an increase in the amount of Span 85 in the formulation, and an Fd3m structure was obtained with a sustained release of LA. A maintained blood concentration of LA over 21 days was confirmed by subcutaneous ( s.c. ) administration of the formulation. No retained administered formulation at the injection site was confirmed 28 days after administration without any signs of irritation, inflammation, or other apparent toxicity confirmed by visual observation. This result may be helpful for the development of a lipid-based formulation of peptides and proteins with sustained drug release.
doi_str_mv 10.3389/fddev.2023.1270584
format article
fullrecord <record><control><sourceid>doaj_cross</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c9c6b2ca48e54baf8776b7e15015be95</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c9c6b2ca48e54baf8776b7e15015be95</doaj_id><sourcerecordid>oai_doaj_org_article_c9c6b2ca48e54baf8776b7e15015be95</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2464-b527753ee4cfe7485b383930e4f1618f84b6696f70199c5b0a11e227d3ad1f7d3</originalsourceid><addsrcrecordid>eNpNkctKBDEQRYMoKOoPuMoP9Jh30kvxDYIbXYd0uuJkSHfapGdk_t4ZR8RFcasK7tkchK4oWXBu2uvQ97BZMML4gjJNpBFH6IwpLRpiJDn-t5-iy1pXhBBmtCBanaHpDjaQ8jTAOOMcsMM9THnGIZdhndwc84i_4rzEbsRxxDXOazzmsUlugJRcwSl-rmOPfdnW2aVm34vjB667E4ZDdVrmupsUp9jXC3QSXKpw-Zvn6P3h_u32qXl5fXy-vXlpPBNKNJ1kWksOIHwALYzsuOEtJyACVdQEIzqlWhU0oW3rZUccpcCY7rnradjFOXo-cPvsVnYqcXBla7OL9ueRy4d1ZY4-gfWtVx3zThiQonPBaK06DVQSKjto5Y7FDixfcq0Fwh-PErtXYH8U2L0C-6uAfwOyIHyh</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Development of a depot formulation with an in situ non-lamellar liquid crystal-forming system with phospholipids</title><source>Alma/SFX Local Collection</source><creator>Todo, Hiroaki ; Niki, Rina ; Okada, Akie ; Narita, Ibuki ; Inamura, Kazuya ; Ito, Ayu ; Itakura, Shoko ; Hijikuro, Ichiro ; Sugibayashi, Kenji</creator><creatorcontrib>Todo, Hiroaki ; Niki, Rina ; Okada, Akie ; Narita, Ibuki ; Inamura, Kazuya ; Ito, Ayu ; Itakura, Shoko ; Hijikuro, Ichiro ; Sugibayashi, Kenji</creatorcontrib><description>Non-lamellar liquid crystal (NLLC) structures have gained increasing attention for the controlled release of entrapped drugs. In the present study, an in situ NLLC structure-forming depot formulation through contact with water was developed using a ternary mixture system of soya phosphatidyl choline (SPC), 1, 2-dioleoyl- sn -glycero-3-phosphoglycerol sodium salt (DOPG), and sorbitan trioleate (Span 85), and the long-term release of an entrapped model drug, leuprolide acetate (LA), was investigated using evaluation of in vitro release and in vivo blood concentration–time profiles. Polarized images and small angle X-ray scattering analysis were used to confirm the presence of NLLC structures by contacting the prepared formulation with water. In addition, LA release and blood concentration–time profiles were investigated using in vitro and in vivo experiments, respectively. In situ NLLC constructed formulations by contacting water were achieved using a ternary mixture of SPC, DOPG, and Span 85. In particular, negative curvature was increased with an increase in the amount of Span 85 in the formulation, and an Fd3m structure was obtained with a sustained release of LA. A maintained blood concentration of LA over 21 days was confirmed by subcutaneous ( s.c. ) administration of the formulation. No retained administered formulation at the injection site was confirmed 28 days after administration without any signs of irritation, inflammation, or other apparent toxicity confirmed by visual observation. This result may be helpful for the development of a lipid-based formulation of peptides and proteins with sustained drug release.</description><identifier>ISSN: 2674-0850</identifier><identifier>EISSN: 2674-0850</identifier><identifier>DOI: 10.3389/fddev.2023.1270584</identifier><language>eng</language><publisher>Frontiers Media S.A</publisher><subject>in situ forming system ; lipid-based depot formulation ; long-acting drug delivery system ; non-lamellar liquid crystal ; sustained release</subject><ispartof>Frontiers in Drug Delivery, 2023-10, Vol.3</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2464-b527753ee4cfe7485b383930e4f1618f84b6696f70199c5b0a11e227d3ad1f7d3</citedby><cites>FETCH-LOGICAL-c2464-b527753ee4cfe7485b383930e4f1618f84b6696f70199c5b0a11e227d3ad1f7d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Todo, Hiroaki</creatorcontrib><creatorcontrib>Niki, Rina</creatorcontrib><creatorcontrib>Okada, Akie</creatorcontrib><creatorcontrib>Narita, Ibuki</creatorcontrib><creatorcontrib>Inamura, Kazuya</creatorcontrib><creatorcontrib>Ito, Ayu</creatorcontrib><creatorcontrib>Itakura, Shoko</creatorcontrib><creatorcontrib>Hijikuro, Ichiro</creatorcontrib><creatorcontrib>Sugibayashi, Kenji</creatorcontrib><title>Development of a depot formulation with an in situ non-lamellar liquid crystal-forming system with phospholipids</title><title>Frontiers in Drug Delivery</title><description>Non-lamellar liquid crystal (NLLC) structures have gained increasing attention for the controlled release of entrapped drugs. In the present study, an in situ NLLC structure-forming depot formulation through contact with water was developed using a ternary mixture system of soya phosphatidyl choline (SPC), 1, 2-dioleoyl- sn -glycero-3-phosphoglycerol sodium salt (DOPG), and sorbitan trioleate (Span 85), and the long-term release of an entrapped model drug, leuprolide acetate (LA), was investigated using evaluation of in vitro release and in vivo blood concentration–time profiles. Polarized images and small angle X-ray scattering analysis were used to confirm the presence of NLLC structures by contacting the prepared formulation with water. In addition, LA release and blood concentration–time profiles were investigated using in vitro and in vivo experiments, respectively. In situ NLLC constructed formulations by contacting water were achieved using a ternary mixture of SPC, DOPG, and Span 85. In particular, negative curvature was increased with an increase in the amount of Span 85 in the formulation, and an Fd3m structure was obtained with a sustained release of LA. A maintained blood concentration of LA over 21 days was confirmed by subcutaneous ( s.c. ) administration of the formulation. No retained administered formulation at the injection site was confirmed 28 days after administration without any signs of irritation, inflammation, or other apparent toxicity confirmed by visual observation. This result may be helpful for the development of a lipid-based formulation of peptides and proteins with sustained drug release.</description><subject>in situ forming system</subject><subject>lipid-based depot formulation</subject><subject>long-acting drug delivery system</subject><subject>non-lamellar liquid crystal</subject><subject>sustained release</subject><issn>2674-0850</issn><issn>2674-0850</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpNkctKBDEQRYMoKOoPuMoP9Jh30kvxDYIbXYd0uuJkSHfapGdk_t4ZR8RFcasK7tkchK4oWXBu2uvQ97BZMML4gjJNpBFH6IwpLRpiJDn-t5-iy1pXhBBmtCBanaHpDjaQ8jTAOOMcsMM9THnGIZdhndwc84i_4rzEbsRxxDXOazzmsUlugJRcwSl-rmOPfdnW2aVm34vjB667E4ZDdVrmupsUp9jXC3QSXKpw-Zvn6P3h_u32qXl5fXy-vXlpPBNKNJ1kWksOIHwALYzsuOEtJyACVdQEIzqlWhU0oW3rZUccpcCY7rnradjFOXo-cPvsVnYqcXBla7OL9ueRy4d1ZY4-gfWtVx3zThiQonPBaK06DVQSKjto5Y7FDixfcq0Fwh-PErtXYH8U2L0C-6uAfwOyIHyh</recordid><startdate>202310</startdate><enddate>202310</enddate><creator>Todo, Hiroaki</creator><creator>Niki, Rina</creator><creator>Okada, Akie</creator><creator>Narita, Ibuki</creator><creator>Inamura, Kazuya</creator><creator>Ito, Ayu</creator><creator>Itakura, Shoko</creator><creator>Hijikuro, Ichiro</creator><creator>Sugibayashi, Kenji</creator><general>Frontiers Media S.A</general><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>202310</creationdate><title>Development of a depot formulation with an in situ non-lamellar liquid crystal-forming system with phospholipids</title><author>Todo, Hiroaki ; Niki, Rina ; Okada, Akie ; Narita, Ibuki ; Inamura, Kazuya ; Ito, Ayu ; Itakura, Shoko ; Hijikuro, Ichiro ; Sugibayashi, Kenji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2464-b527753ee4cfe7485b383930e4f1618f84b6696f70199c5b0a11e227d3ad1f7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>in situ forming system</topic><topic>lipid-based depot formulation</topic><topic>long-acting drug delivery system</topic><topic>non-lamellar liquid crystal</topic><topic>sustained release</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Todo, Hiroaki</creatorcontrib><creatorcontrib>Niki, Rina</creatorcontrib><creatorcontrib>Okada, Akie</creatorcontrib><creatorcontrib>Narita, Ibuki</creatorcontrib><creatorcontrib>Inamura, Kazuya</creatorcontrib><creatorcontrib>Ito, Ayu</creatorcontrib><creatorcontrib>Itakura, Shoko</creatorcontrib><creatorcontrib>Hijikuro, Ichiro</creatorcontrib><creatorcontrib>Sugibayashi, Kenji</creatorcontrib><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in Drug Delivery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Todo, Hiroaki</au><au>Niki, Rina</au><au>Okada, Akie</au><au>Narita, Ibuki</au><au>Inamura, Kazuya</au><au>Ito, Ayu</au><au>Itakura, Shoko</au><au>Hijikuro, Ichiro</au><au>Sugibayashi, Kenji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a depot formulation with an in situ non-lamellar liquid crystal-forming system with phospholipids</atitle><jtitle>Frontiers in Drug Delivery</jtitle><date>2023-10</date><risdate>2023</risdate><volume>3</volume><issn>2674-0850</issn><eissn>2674-0850</eissn><abstract>Non-lamellar liquid crystal (NLLC) structures have gained increasing attention for the controlled release of entrapped drugs. In the present study, an in situ NLLC structure-forming depot formulation through contact with water was developed using a ternary mixture system of soya phosphatidyl choline (SPC), 1, 2-dioleoyl- sn -glycero-3-phosphoglycerol sodium salt (DOPG), and sorbitan trioleate (Span 85), and the long-term release of an entrapped model drug, leuprolide acetate (LA), was investigated using evaluation of in vitro release and in vivo blood concentration–time profiles. Polarized images and small angle X-ray scattering analysis were used to confirm the presence of NLLC structures by contacting the prepared formulation with water. In addition, LA release and blood concentration–time profiles were investigated using in vitro and in vivo experiments, respectively. In situ NLLC constructed formulations by contacting water were achieved using a ternary mixture of SPC, DOPG, and Span 85. In particular, negative curvature was increased with an increase in the amount of Span 85 in the formulation, and an Fd3m structure was obtained with a sustained release of LA. A maintained blood concentration of LA over 21 days was confirmed by subcutaneous ( s.c. ) administration of the formulation. No retained administered formulation at the injection site was confirmed 28 days after administration without any signs of irritation, inflammation, or other apparent toxicity confirmed by visual observation. This result may be helpful for the development of a lipid-based formulation of peptides and proteins with sustained drug release.</abstract><pub>Frontiers Media S.A</pub><doi>10.3389/fddev.2023.1270584</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2674-0850
ispartof Frontiers in Drug Delivery, 2023-10, Vol.3
issn 2674-0850
2674-0850
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_c9c6b2ca48e54baf8776b7e15015be95
source Alma/SFX Local Collection
subjects in situ forming system
lipid-based depot formulation
long-acting drug delivery system
non-lamellar liquid crystal
sustained release
title Development of a depot formulation with an in situ non-lamellar liquid crystal-forming system with phospholipids
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A11%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20depot%20formulation%20with%20an%20in%20situ%20non-lamellar%20liquid%20crystal-forming%20system%20with%20phospholipids&rft.jtitle=Frontiers%20in%20Drug%20Delivery&rft.au=Todo,%20Hiroaki&rft.date=2023-10&rft.volume=3&rft.issn=2674-0850&rft.eissn=2674-0850&rft_id=info:doi/10.3389/fddev.2023.1270584&rft_dat=%3Cdoaj_cross%3Eoai_doaj_org_article_c9c6b2ca48e54baf8776b7e15015be95%3C/doaj_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2464-b527753ee4cfe7485b383930e4f1618f84b6696f70199c5b0a11e227d3ad1f7d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true